Lyell Immunopharma, Inc. (LYEL) Free cash flow 2019–2025
Lyell Immunopharma, Inc. (LYEL) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$150.8MFY2025 · since FY2019: $23.4M → -$150.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$150.8M | +7.4% |
| FY2024 | -$162.9M | +2.1% |
| FY2023 | -$166.4M | +14.2% |
| FY2022 | -$193.8M | -1.1% |
| FY2021 | -$191.8M | +9.7% |
| FY2020 | -$212.4M | -1006.5% |
| FY2019 | $23.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice